Fiche société
Kangpu Biopharmaceuticals, Ltd.
Traitements, essais et publications liés.
Traitements7programmes
Essais1liés
Publications9liées
SourceDBlocale
Traitements
7| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| KPG-818 high dose in phase 1bThe clinical trial is titled "A Phase 1b/2a Multicenter Study to Assess the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of KPG-818 in Patients with Systemic Lupus Erythematosus". This study was designed to address the following key questions: * Phase 1b: Assess safety and PK of KPG-818 in SLE patients over 14 days. * Phase 2a: Assess safety, efficacy, PD biomarkers, and PK of KPG-818 in SLE patients over 12 weeks. The study design comprises eight Cohorts, which are outlined below: * Phase 1b dose levels: Cohort A (0.15 mg/day), B (0.6 mg/day), C (2 mg/day), and D (5 mg/day). * Phase 2a dose levels: Cohort E (0.15 mg/day), F (0.6 mg/day), G (2 mg/day) and H (placebo). | Lupus | Phase 1/2 | À vérifier | United States | À vérifier |
| KPG-818 low dose in phase 1bThe clinical trial is titled "A Phase 1b/2a Multicenter Study to Assess the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of KPG-818 in Patients with Systemic Lupus Erythematosus". This study was designed to address the following key questions: * Phase 1b: Assess safety and PK of KPG-818 in SLE patients over 14 days. * Phase 2a: Assess safety, efficacy, PD biomarkers, and PK of KPG-818 in SLE patients over 12 weeks. The study design comprises eight Cohorts, which are outlined below: * Phase 1b dose levels: Cohort A (0.15 mg/day), B (0.6 mg/day), C (2 mg/day), and D (5 mg/day). * Phase 2a dose levels: Cohort E (0.15 mg/day), F (0.6 mg/day), G (2 mg/day) and H (placebo). | Lupus | Phase 1/2 | À vérifier | United States | À vérifier |
| KPG-818 low dose in phase 2aThe clinical trial is titled "A Phase 1b/2a Multicenter Study to Assess the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of KPG-818 in Patients with Systemic Lupus Erythematosus". This study was designed to address the following key questions: * Phase 1b: Assess safety and PK of KPG-818 in SLE patients over 14 days. * Phase 2a: Assess safety, efficacy, PD biomarkers, and PK of KPG-818 in SLE patients over 12 weeks. The study design comprises eight Cohorts, which are outlined below: * Phase 1b dose levels: Cohort A (0.15 mg/day), B (0.6 mg/day), C (2 mg/day), and D (5 mg/day). * Phase 2a dose levels: Cohort E (0.15 mg/day), F (0.6 mg/day), G (2 mg/day) and H (placebo). | Lupus | Phase 1/2 | À vérifier | United States | À vérifier |
| KPG-818 mid dose in phase 1bThe clinical trial is titled "A Phase 1b/2a Multicenter Study to Assess the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of KPG-818 in Patients with Systemic Lupus Erythematosus". This study was designed to address the following key questions: * Phase 1b: Assess safety and PK of KPG-818 in SLE patients over 14 days. * Phase 2a: Assess safety, efficacy, PD biomarkers, and PK of KPG-818 in SLE patients over 12 weeks. The study design comprises eight Cohorts, which are outlined below: * Phase 1b dose levels: Cohort A (0.15 mg/day), B (0.6 mg/day), C (2 mg/day), and D (5 mg/day). * Phase 2a dose levels: Cohort E (0.15 mg/day), F (0.6 mg/day), G (2 mg/day) and H (placebo). | Lupus | Phase 1/2 | À vérifier | United States | À vérifier |
| KPG-818 mid dose in phase 2aThe clinical trial is titled "A Phase 1b/2a Multicenter Study to Assess the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of KPG-818 in Patients with Systemic Lupus Erythematosus". This study was designed to address the following key questions: * Phase 1b: Assess safety and PK of KPG-818 in SLE patients over 14 days. * Phase 2a: Assess safety, efficacy, PD biomarkers, and PK of KPG-818 in SLE patients over 12 weeks. The study design comprises eight Cohorts, which are outlined below: * Phase 1b dose levels: Cohort A (0.15 mg/day), B (0.6 mg/day), C (2 mg/day), and D (5 mg/day). * Phase 2a dose levels: Cohort E (0.15 mg/day), F (0.6 mg/day), G (2 mg/day) and H (placebo). | Lupus | Phase 1/2 | À vérifier | United States | À vérifier |
| KPG-818 ultra-high dose in phase 1bThe clinical trial is titled "A Phase 1b/2a Multicenter Study to Assess the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of KPG-818 in Patients with Systemic Lupus Erythematosus". This study was designed to address the following key questions: * Phase 1b: Assess safety and PK of KPG-818 in SLE patients over 14 days. * Phase 2a: Assess safety, efficacy, PD biomarkers, and PK of KPG-818 in SLE patients over 12 weeks. The study design comprises eight Cohorts, which are outlined below: * Phase 1b dose levels: Cohort A (0.15 mg/day), B (0.6 mg/day), C (2 mg/day), and D (5 mg/day). * Phase 2a dose levels: Cohort E (0.15 mg/day), F (0.6 mg/day), G (2 mg/day) and H (placebo). | Lupus | Phase 1/2 | À vérifier | United States | À vérifier |
| KPG-818 low dose in phase 1bThe clinical trial is titled "A Phase 1b/2a Multicenter Study to Assess the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of KPG-818 in Patients with Systemic Lupus Erythematosus". This study was designed to address the following key questions: * Phase 1b: Assess safety and PK of KPG-818 in SLE patients over 14 days. * Phase 2a: Assess safety, efficacy, PD biomarkers, and PK of KPG-818 in SLE patients over 12 weeks. The study design comprises eight Cohorts, which are outlined below: * Phase 1b dose levels: Cohort A (0.15 mg/day), B (0.6 mg/day), C (2 mg/day), and D (5 mg/day). * Phase 2a dose levels: Cohort E (0.15 mg/day), F (0.6 mg/day), G (2 mg/day) and H (placebo). | Lupus | Phase 1/2 | À vérifier | United States | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| KPG-818 low dose in phase 1b | Lupus | Phase 1/2 | NCT04643067 | Lupus — Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE | COMPLETED |
Publications
9| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| KPG-818 low dose in phase 2a | Efficacy and safety of oxfendazole in adults with spp. infection in Pemba Island, Tanzania: a double-blind, phase 2a, randomised controlled trial. | EClinicalMedicine | ||
| KPG-818 mid dose in phase 2a | Novel Controlled Metabolic Accelerator for Obesity-Related HFpEF: The HuMAIN-HFpEF Randomized Clinical Trial. | JAMA cardiology | ||
| KPG-818 high dose in phase 1b | TheraPb Phase 1b: First-in-Human Dose-Escalation and Optimization Study of Pb-ADVC001 in PSMA-Positive Metastatic Androgen Pathway Modulation-Resistant Prostate Cancer. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine | ||
| KPG-818 mid dose in phase 1b | Autologous bone marrow mesenchymal stromal cell therapy for "no-option" critical limb ischemia is limited by karyotype abnormalities. | Cytotherapy | ||
| KPG-818 mid dose in phase 1b | Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b/2 trial. | Nature medicine | ||
| KPG-818 mid dose in phase 1b | Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study. | Blood advances | ||
| KPG-818 low dose in phase 1b | A first-in-human Phase 1/1b randomized trial evaluating the safety and immunogenicity of a respiratory syncytial virus (RSV) virus-like particle subunit vaccine (IVX-121) in healthy young and older adults. | Human vaccines & immunotherapeutics | ||
| KPG-818 low dose in phase 1b | Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial. | mAbs | ||
| KPG-818 low dose in phase 1b | for latent virus reactivation in people living with HIV on suppressive antiretroviral therapy: A phase 1b/2a clinical trial. | Journal of virus eradication |